Interleukin-6 as an emerging regulator of renal cell cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 11, 2015, Pages 476-485

  Kamińska, Katarzyna ^a   Czarnecka, Anna M ^a   Escudier, Bernard ^b   Lian, Fei ^c   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Interleukin 6; Metastasis; Renal cancer

Indexed keywords

INTERLEUKIN 6; ANTINEOPLASTIC AGENT; IL6 PROTEIN, HUMAN;

ADIPOCYTE; B LYMPHOCYTE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CARTILAGE CELL; CELL PROLIFERATION; DISEASE PREDISPOSITION; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; KERATINOCYTE; KIDNEY CARCINOMA; LIVER CELL; MEGAKARYOCYTE; MESANGIUM CELL; METASTASIS; NEUTROPHIL; NONHUMAN; OSTEOBLAST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DRUG EFFECTS; KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INTERLEUKIN-6; KIDNEY NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84945459616     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.07.010     Document Type: Review

References (101)

1. Bruno J.J., Snyder M.E., Motzer R.J., Russo P. Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU Int 2006, 97:933-938.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J Clin 2009, 59(2009):225-249.
3. Bex A., Jonasch E., Kirkali Z., Mejean A., Mulders P., Oudard S., et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol 2010, 58:819-828.
4. Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol 2012, 23(Suppl. 8):35-40.
5. Strube A., Stepina E., Mumberg D., Scholz A., Hauff P., Kakonen S.M. Characterization of a new renal cell carcinoma bone metastasis mouse model. Clin Exp Metastasis 2010, 27:319-330.
6. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
7. Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. N Engl J Med 1996, 335:865-875.
8. Motzer R.J., Bacik J., Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Can Res 2004, 10:6302S-6303S.
9. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
10. Medical Research Council Renal Cancer Collaborators Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999, 353:14-17.
11. Grunwald V., Desar I.M., Haanen J., Fiedler W., Mouritzen U., Olsen M.W., et al. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). Acta Oncol 2011, 50:121-126.
12. Rossi J.F., Negrier S., James N.D., Kocak I., Hawkins R., Davis H., et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010, 103:1154-1162.
13. Czarnecka A.M., Kukwa W., Kornakiewicz A., Lian F., Szczylik C. Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer. Future Oncol 2014, 10:2493-2508.
14. Czarnecka A.M., Kornakiewicz A., Kukwa W., Szczylik C. Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma. Future Oncol 2014, 10:1095-1111.
15. Miller J.F., Mitchell G.F. Cell to cell interaction in the immune response. I. Hemolysin-forming cells in neonatally thymectomized mice reconstituted with thymus or thoracic duct lymphocytes,. J Exp Med 1968, 128:801-820.
16. Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986, 324:73-76.
17. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthr Res Ther 2006, (Suppl. 2):S2.
18. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010, 22:347-352.
19. Yasukawa K., Hirano T., Watanabe Y., Muratani K., Matsuda T., Nakai S., et al. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J 1987, 6:2939-2945.
20. Mihara M., Hashizume M., Yoshida H., Suzuki M., Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012, 122:143-159.
21. Chang S.G., Lee S.J., Kimi J.I., Jung J.C., Kim J.H., Hoffman R.M. Interleukin-6 production in primary histoculture by normal human kidney and renal tumor tissues. Anticancer Res 1997, 17:113-115.
22. Yao X., Huang J., Zhong H., Shen N., Faggioni R., Fung M., et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014, 141:125-139.
23. Wolf J., Rose-John S., Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 2014, 70:11-20.
24. Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990, 63:1149-1157.
25. Mullberg J., Schooltink H., Stoyan T., Gunther M., Graeve L., Buse G., et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993, 23:473-480.
26. Mullberg J., Oberthur W., Lottspeich F., Mehl E., Dittrich E., Graeve L., et al. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol 1994, 152:4958-4968.
27. Jones S.A., Horiuchi S., Topley N., Yamamoto N., Fuller G.M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001, 15:43-58.
28. Chalaris A., Garbers C., Rabe B., Rose-John S., Scheller J. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 2011, 90:484-494.
29. Qi Q.R., Yang Z.M. Regulation and function of signal transducer and activator of transcription 3. World J Biol Chem 2014, 5:231-239.
30. Horiguchi A., Oya M., Shimada T., Uchida A., Marumo K., Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 2002, 168:762-765.
31. Sehgal P.B. Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol 2008, 19:329-340.
32. Catalano R.D., Johnson M.H., Campbell E.A., Charnock-Jones D.S., Smith S.K., Sharkey A.M. Inhibition of Stat3 activation in the endometrium prevents implantation: a nonsteroidal approach to contraception. Proc Natl Acad Sci U S A 2005, 102:8585-8590.
33. Grandis J.R., Drenning S.D., Zeng Q., Watkins S.C., Melhem M.F., Endo S., et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000, 97:4227-4232.
34. Chatterjee M., Jain S., Stuhmer T., Andrulis M., Ungethum U., Kuban R.J., et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007, 109:720-728.
35. Dhir R., Ni Z., Lou W., DeMiguel F., Grandis J.R., Gao A.C. Stat3 activation in prostatic carcinomas. Prostate 2002, 51:241-246.
36. Hambek M., Baghi M., Strebhardt K., May A., Adunka O., Gstottner W., et al. STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR. Anticancer Res 2004, 24:3881-3886.
37. Proietti C.J., Rosemblit C., Beguelin W., Rivas M.A., Diaz Flaque M.C., Charreau E.H., et al. Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Mol Cell Biol 2009, 29:1249-1265.
38. Matsumoto S., Hara T., Mitsuyama K., Yamamoto M., Tsuruta O., Sata M., et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 2010, 184:1543-1551.
39. Blay J.Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992, 52:3317-3322.
40. Costes V., Liautard J., Picot M.C., Robert M., Lequeux N., Brochier J., et al. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J Clin Pathol 1997, 50:835-840.
41. Walther M.M., Johnson B., Culley D., Shah R., Weber J., Venzon D., et al. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol 1998, 159:718-722.
42. Polimeno M., Napolitano M., Costantini S., Portella L., Esposito A., Capone F., et al. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU Int 2013, 112:686-696.
43. Sievers E., Dreimuller P., Haferkamp A., Schmidt-Wolf I.G., Buchler M.W., Schmidt J., et al. Characterization of primary renal carcinoma cultures. Urol Int 2007, 79:235-243.
44. Alberti L., Thomachot M.C., Bachelot T., Menetrier-Caux C., Puisieux I., Blay J.Y. IL-6 as an intracrine growth factor for renal carcinoma cell lines, International journal of cancer. Int J Cancer 2004, 111:653-661.
45. Takenawa J., Kaneko Y., Fukumoto M., Fukatsu A., Hirano T., Fukuyama H., et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 1991, 83:1668-1672.
46. Mackiewicz-Wysocka M.K.A., Kwias Z., Mackiewicz A. Expression of interleukin-6 and its receptor subunits in the microenvironment of renal cell cancer. Wspolcz Onkol 2001, 5:45-47.
47. Sakai A., Kawano M., Kuramoto A. Interleukin-6 produced by renal-cell carcinoma cells and progression of multiple myeloma. N Engl J Med 1991, 324:1893-1894.
48. Fitzgerald J.P., Nayak B., Shanmugasundaram K., Friedrichs W., Sudarshan S., Eid A.A., et al. Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production. PloS One 2012, 7:e30712.
49. Yanase M., Tsukamoto T., Kumamoto Y. Cytokines modulate in vitro invasiveness of renal cell carcinoma cells through action on the process of cell attachment to endothelial cells. J Urol 1995, 153:844-848.
50. Chuang M.J., Sun K.H., Tang S.J., Deng M.W., Wu Y.H., Sung J.S., et al. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008, 99:905-913.
51. Kaminska K.C.M.A., Szczylik C. Hypoxia and IL-6 as Regulators of Clear Cell Renal Cell Cancer Viability, in: 5th International Conference on Stem Cells and Cancer (ICSCC-2014): Proliferation, Differentiation and Apoptosis 2014, 7-8. Angkor Publishers (P) Ltd., New Delhi.
52. Gruss H.J., Brach M.A., Mertelsmann R.H., Herrmann F. Interferon-gamma interrupts autocrine growth mediated by endogenous interleukin-6 in renal-cell carcinoma, International journal of cancer. Int J Cancer 1991, 49:770-773.
53. Angelo L.S., Talpaz M., Kurzrock R. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res 2002, 62:932-940.
54. Santoni M., Massari F., Amantini C., Nabissi M., Maines F., Burattini L., et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2013, 62:1757-1768.
55. Figel A.M., Brech D., Prinz P.U., Lettenmeyer U.K., Eckl J., Turqueti-Neves A., et al. Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations. Am J Pathol 2011, 179:436-451.
56. Noessner E., Brech D., Mendler A.N., Masouris I., Schlenker R., Prinz P.U. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology 2012, 1:1451-1453.
57. Lamb G.W., McArdle P.A., Ramsey S., McNichol A.M., Edwards J., Aitchison M., et al. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int 2008, 102:756-761.
58. Horiguchi A., Oya M., Marumo K., Murai M. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Inter 2002, 61:926-938.
59. Jung J.E., Lee H.G., Cho I.H., Chung D.H., Yoon S.H., Yang Y.M., et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 2005, 19:1296-1298.
60. Fang Z., Tang Y., Fang J., Zhou Z., Xing Z., Guo Z., et al. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PloS One 2013, 8:e62823.
61. Kakugawa Y., Wada T., Yamaguchi K., Yamanami H., Ouchi K., Sato I., et al. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc Natl Acad Sci U S A 2002, 99:10718-10723.
62. Masson D., Rioux-Leclercq N., Fergelot P., Jouan F., Mottier S., Theoleyre S., et al. Loss of expression of TIMP3 in clear cell renal cell carcinoma. Eur J Cancer 2010, 46:1430-1437.
63. Cuadros T., Trilla E., Sarro E., Vila M.R., Vilardell J., de Torres I., et al. HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome. Cancer Res 2014, 74:1416-1428.
64. Ueno S., Saito S., Wada T., Yamaguchi K., Satoh M., Arai Y., et al. Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes interleukin-6-induced apoptosis suppression and cell motility. J Biol Chem 2006, 281:7756-7764.
65. Favaro D., Santarosa M., Quaia M., Galligioni E. Interleukin-6 and soluble intercellular adhesion molecule-1 in renal cancer patients and cultured renal cancer cells. Urol Oncol 1997, 3:51-58.
66. Hrab M., Olek-Hrab K., Antczak A., Kwias Z., Milecki T. Interleukin-6 (IL-6) and C-reactive protein (CRP) concentration prior to total nephrectomy are prognostic factors in localized renal cell carcinoma (RCC). Rep Pract Oncol Radiother 2013, 18:304-309.
67. Negrier S., Perol D., Menetrier-Caux C., Escudier B., Pallardy M., Ravaud A., et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-From the Groupe Francais d'Immunotherapie. J Clin Oncol 2004, 22:2371-2378.
68. Dosquet C., Schaetz A., Faucher C., Lepage E., Wautier J.L., Richard F., et al. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 1994, 30A:162-167.
69. Paule B., Belot J., Rudant C., Coulombel C., Abbou C.C. The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study. J Clin Pathol 2000, 53:388-390.
70. Blay J.Y., Rossi J.F., Wijdenes J., Menetrier-Caux C., Schemann S., Negrier S., et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma, International journal of cancer. Int J Cancer 1997, 72:424-430.
71. Adler G., Eichman W., Szczepanski M., Targonska I., Jasinska A. Postoperative plasma interleukin-6 in patients with renal cancer correlates with C-reactive protein but not with total fibrinogen or with high molecular weight fibrinogen fraction. Thrombosis Res 1998, 89:243-248.
72. Tran H.T., Liu Y., Zurita A.J., Lin Y., Baker-Neblett K.L., Martin A.M., et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials, The Lancet. Oncology 2012, 13:827-837.
73. Coley WB. The treatment of malignant inoperable tumors with the mixed toxins of erysipelas and bacillus prodigiosus. Brussels: M Weissenbruch; 1914.
74. Alexandrescu D.T., Dasanu C.A. Kidney cancer therapy: new perspectives and avenues. Expert Opin Pharmacother 2006, 7:2481-2493.
75. Passalacqua R., Buti S., Tomasello G., Longarini R., Brighenti M., Dalla Chiesa M. Immunotherapy options in metastatic renal cell cancer: where we are and where we are going. Expert Rev Anticancer Ther 2006, 6:1459-1472.
76. Yang J.C., Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 2006, 24:5576-5583.
77. Motzer R.J., Bukowski R.M. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006, 24:5601-5608.
78. Belardelli F., Ferrantini M., Proietti E., Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002, 13:119-134.
79. Margolin K.A. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000, 27:194-203.
80. Tourani J.M., Pfister C., Tubiana N., Ouldkaci M., Prevot G., Lucas V., et al. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design-the Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol 2003, 21:3987-3994.
81. Yang J.C.Y. Interleukin-2: Clinical Aplications Renal Cell Carcinoma 2000, Lippincott, Philadelphia. 3rd ed.
82. Leibovich B.C., Han K.R., Bui M.H., Pantuck A.J., Dorey F.J., Figlin R.A., et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 98:2566-2575.
83. McDermott D.F., Regan M.M., Clark J.I., Flaherty L.E., Weiss G.R., Logan T.F., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005, 23:133-141.
84. Atkins M.B., Ernstoff M.S., Figlin R.A., Flaherty K.T., George D.J., Kaelin W.G., et al. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res 2007, 13:667s-670s.
85. Motzer R.J., Molina A.M. Targeting renal cell carcinoma. J Clin Oncol 2009, 27:3274-3276.
86. Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, et al. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer 2004;101:90-5.
87. Liu Z., Wang Z., Xiao Y., Lu Y. Association between the interleukin-6 gene polymorphisms and renal cancer risk. Immunol Lett 2015, 164:125-128.
88. Trikha M., Corringham R., Klein B., Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003, 9:4653-4665.
89. Mizutani Y., Bonavida B., Koishihara Y., Akamatsu K., Ohsugi Y., Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995, 55:590-596.
90. Lin J.C., Liu C.L., Lee J.J., Liu T.P., Ko W.C., Huang Y.C., et al. Sorafenib induces autophagy and suppresses activation of human macrophage. Int Immunopharmacol 2013, 15:333-339.
91. Li S., Priceman S.J., Xin H., Zhang W., Deng J., Liu Y., et al. Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PloS One 2013, 8:e81657.
92. Miki S., Iwano M., Miki Y., Yamamoto M., Tang B., Yokokawa K., et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989, 250:607-610.
93. Weissglas M., Schamhart D., Lowik C., Papapoulos S., Vos P., Kurth K.H. Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice. J Urol 1995, 153:854-857.
94. Porta C., Pedrazzoli P., Paglino C. Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab. Immunotherapy 2011, 3:487-490.
95. Schipperus M., Cornfeld M., Rijnbeek B., Berns B., Rossi J. CNTO328 (Anti-IL-6 mAb) treatment and hemoglobin (Hb) levels in renal cell cancer. J Clin Oncol 2009, 27.
96. Thurnher M., Nussbaumer O., Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 2012, 18:3524-3531.
97. Oguro T., Ishibashi K., Sugino T., Hashimoto K., Tomita S., Takahashi N., et al. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression. Eur J Cancer 2013, 49:1715-1724.
98. Tomita S., Ishibashi K., Hashimoto K., Sugino T., Yanagida T., Kushida N., et al. Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-alpha. Cancer Sci 2011, 102:57-63.
99. Lacroix M , Buatois V, Johnson Z, Kosco-Vilbois MH, Ferlin WG. 50: novel insights into IL-6 biology revealed by selective targeting of TRANS-signaling, Cytokine 2014;70:1-40.
100. Cabillic F., Bouet-Toussaint F., Toutirais O., Rioux-Leclercq N., Fergelot P., de la Pintiere C.T., et al. Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk. Clin Exp Immunol 2006, 146:518-523.
101. Guo Y.Q., Xu F., Lu T.H., Duan Z.F., Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012, 38:904-910.